CYP 006TK
Alternative Names: Cymerus mesenchymal stem cells; CYP-006TKLatest Information Update: 16 Apr 2024
At a glance
- Originator Cynata Therapeutics
- Class Induced pluripotent stem cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diabetic foot ulcer
Most Recent Events
- 08 Apr 2024 Cynata Therapeutics completes enrollment in a phase I trial in Diabetic foot ulcers in Australia (Topical)
- 27 Feb 2024 Interim efficacy data from a phase I trial in Diabetic foot ulcers released by Cynata Therapeutics
- 30 Mar 2022 Pharmacodynamics data from preclinical trial in Diabetic foot ulcer released by Cynata Therapeutics before March 2022 (Cynata Therapeutics' March 2022)